Agenus presents new translational data at 2025 ASCO meeting

Agenus (AGEN) presented new translational data at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable, MSS, or mismatch repair proficient, pMMR, metastatic colorectal cancer-a tumor type traditionally resistant to immunotherapy and representing approximately 85-95% of all colorectal cancers. T cells are key immune cells capable of recognizing and attacking cancer cells. Activating these typically ‘cold’ tumors and driving a strong T cell response suggests that botensilimab has the potential to overcome resistance and improve patient outcomes. Data Highlights: Fast T cell priming and activation: T-cells begin activating within two weeks of starting botensilimab. Robustly expands and sustains T cell activity: Newly primed T cells persist and expand across treatment cycles, correlating with improved clinical responses. Immune activity detected before scans: Immune-profiling tests detect this activity even when standard imaging hasn’t yet caught a response. Blood signals predict benefit: A quick blood draw can reveal early immune markers that help doctors identify who is most likely to respond and live longer.